![]() | |
Clinical data | |
---|---|
Trade names | Miebo |
Other names | NOV03; 1-(perfluorohexyl)octane |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a623054 |
License data | |
Routes of administration | Eye drops |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C14H17F13 |
Molar mass | 432.269 g·mol−1 |
3D model ( JSmol) | |
| |
|
Perfluorohexyloctane, sold under the brand names EvoTears [2] (Europe), NovaTears [3] (Australia, New Zealand), and Miebo [4] (USA), is a medication used for the treatment of dry eye disease. [1] It is a semifluorinated alkane. [1]
Perfluorohexyloctane has been available in multiple markets since 2015 under the brand names EvoTears and NovaTears, [5] and was additionally approved for medical use in the United States in May 2023 under the brand Miebo. [1] [6] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [7]
Perfluorohexyloctane when sold under the brand names EvoTears or NovaTears is available in multiple countries over-the-counter [8] costing NZ$34.00, [9] AUD: $30, [10] €30 [11] for approximately a one-month supply. When sold in the USA under the brand Miebo a prescription is required.
Perfluorohexyloctane is indicated for the treatment of the signs and symptoms of dry eye disease. [1] [12] [13]